Bradykinin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 02.09.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Bradykinin is a biologically active oligopeptide with a molecular mass of about 1,000 daltons, consisting of 9 amino acids. The exact amino acid sequence is:

H2N-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH. Bradykinin is released by the degradation of a high molecular weight kininogen by kallikreins. Bradykinin is involved in plasma extravasation, bronchoconstriction, nociception, vasodilation, and inflammation. It has an effect similar to histamine. It has a chemotactic effect on leukocytes and is a component of bee venom (see insect venom allergy below), among others.

Bradykinin mediates inflammation by causing vasodilation, increasing vascular permeability, and stimulating the synthesis of prostaglandins. Bradykinin causes pain by directly stimulating primary sensory neurons and causing the release of substance P, neurokinin, and calcitonin gene-related peptide. Its bronchoconstrictor action is associated with asthma and rhinitis. It increases renal blood flow by vasodilation and causes natriuresis by inhibiting sodium reabsorption. Bradykinin is degraded by peptidases.

Bradykinin develops its effects by binding to bradykinin receptors. This results primarily in the vasodilatory, antiproliferative, antihypertrophic, antifibrotic, antithrombotic, and antioxidant properties associated with the release of endothelial factors such as nitric oxide, prostacyclin, and tissue plasminogen activator.

General informationThis section has been translated automatically.

Bradykinin is an oligopeptide with a molecular mass of about 1,000 daltons, consisting of 9 amino acids. The exact amino acid sequence is:

H2N-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH.

Bradykinin is released by kininogenases such as kallikrein by proteolytic cleavage from its inactive precursor proteins, kininogens. In humans, bradykinin is degraded by three kininases:

  • Angiotensin Converting Enzyme ( ACE)
  • Aminopeptidase P (APP)
  • Carboxypeptidase N (CPN).

Bradykinin is involved in allergic and anaphylactic reactions. It is essential mediator of angioedema and allergic reactions. Bradykinin is a potent endothelium-dependent vasodilator, causes contraction of non-vascular smooth muscle, increases vascular permeability, and is also involved in the pain mechanism. Bradykinin has an effect similar to histamine. It has a chemotactic effect on leukocytes and is, among other things, a component of bee venom (see below Insect venom allergy).

Note(s)This section has been translated automatically.

Bradykinin is thought to be responsible for the known side effects of ACE inhibitors such as cough, pruritus, urticaria, and angioedema.

In ACE inhibitor-induced angioedema, bradykinin degradation is impaired. Doubling of bradykinin levels in the blood may occur.

Dialysis: Bradykinin (BK) has been identified as a major mediator of hypersensitivity reactions in patients dialyzed with negatively charged membranes and concomitantly treated with angiotensin-converting enzyme (ACE) inhibitors.

LiteratureThis section has been translated automatically.

  1. Dendorfer A et al (2001) Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. At J Physiol Heart Circ Physiol 280: 82-118
  2. Graefe KH et al. (2016) Pharmaceuticals with an effect on the vascular system. In: Graefe KH et al. (Eds) Pharmacology and Toxicology. Georg Thieme Publisher Stuttgart p.171

Authors

Last updated on: 02.09.2022